DNLI
Denali Therapeutics Inc
Price:  
13.81 
USD
Volume:  
796,142.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

DNLI WACC - Weighted Average Cost of Capital

The WACC of Denali Therapeutics Inc (DNLI) is 7.5%.

The Cost of Equity of Denali Therapeutics Inc (DNLI) is 7.55%.
The Cost of Debt of Denali Therapeutics Inc (DNLI) is 5.00%.

Range Selected
Cost of equity 6.60% - 8.50% 7.55%
Tax rate -% - 0.10% 0.05%
Cost of debt 5.00% - 5.00% 5.00%
WACC 6.6% - 8.5% 7.5%
WACC

DNLI WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.6 0.64
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.60% 8.50%
Tax rate -% 0.10%
Debt/Equity ratio 0 0
Cost of debt 5.00% 5.00%
After-tax WACC 6.6% 8.5%
Selected WACC 7.5%